Curis, Inc. (NASDAQ:CRIS)
CAPS Rating:
A drug discovery and development company that is seeking to leverage its innovative biological signaling pathway drug technologies to create new medicines primarily in the field of cancer.
RSS Headlines
Fool UK
Recs
Pattern length